Drugs / conjugated estrogen
conjugated estrogen
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02729701 | May 2016 → Jan 2019 | breast cancer | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 35 trials · 1 met primary | ||||||
| Phase 3 | NCT00238732 | Oct 2005 → Mar 2007 | postmenopausal atrophic vaginitis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00242710 | Sep 2005 → Sep 2008 | endometrial disorder, osteoporosis | Pfizer | Completed | Met primary |
| Phase 3 | NCT00137371 | Aug 2005 → Sep 2007 | postmenopausal atrophic vaginitis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00000605 | Aug 1996 → Jul 2002 | coronary atherosclerosis, myocardial ischemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 3 | NCT00000601 | Jul 1995 → Jun 2000 | intermediate coronary syndrome | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 44 trials · 1 met primary | ||||||
| Phase 4 | NCT05059626 | Dec 2023 → Dec 2025 overdue | endometriosis | Penn State University | Recruiting | No outcome recorded |
| Phase 4 | NCT03740009 | Jan 2019 → May 2021 | major depressive disorder, menstrual disorder | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 4 | NCT02835846 | Sep 2016 → Mar 2018 | overactive bladder | Loyola University | Completed | No outcome recorded |
| Phase 4 | NCT01958073 | Oct 2013 → Dec 2017 | urinary tract infection | University of California, San Diego | Completed | Met primary |
| Phase not applicable1 trial | ||||||
| — | NCT02524769 | Dec 2015 → Nov 2016 | overactive bladder | Loyola University | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 1/2 | NCT03663543 Comparator | Aug 2016 → Jan 2027 expected | ischemic disease | University of Pennsylvania | Active not recruiting | No outcome recorded |
| Phase 3 | NCT00803335 Comparator | Dec 2008 → May 2011 | pelvic organ prolapse, postmenopausal atrophic vaginitis | TriHealth Inc. | Completed | No outcome recorded |
| Phase 4 | NCT03032848 Comparator | Nov 2013 → Dec 2016 | endometrial disorder, pelvic organ prolapse, postmenopausal atrophic vaginitis | Federal University of Paraná | Completed | No outcome recorded |
| — | NCT04301934 Comparator | Jun 2020 → Apr 2023 | urinary tract infection | Mayo Clinic | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Conjugated Estrogen | “Subjects with rest angina and no contraindications to hormone therapy were randomized to receive intravenous followed by oral conjugated estrogen for 21 days, intravenous...” NCT00000601 ↗14“This protocol is designed to study the effect and safety of 2 low-dose regimens of conjugated estrogen cream (PVC) given vaginally in postmenopausal women with atrophic vaginitis.” NCT00137371 ↗ “Subjects were randomized to conjugated estrogen with daily medroxyprogesterone or placebo within two weeks of bypass surgery.” NCT00000605 ↗ “Participants are provided a vaginal estrogen cream (i.e., Premarin Cream® 0.625 mg conjugated estrogen/gram)” NCT02835846 ↗ “Once daily tablet of Duavee (Bazedoxifene (20 mg) plus conjugated estrogen (0.45 mg))” NCT02729701 ↗ “30 days of bazedoxifene + conjugated estrogen (0.45mg/20mg/day)” NCT05059626 ↗ |
| Known as | Premarin cream | “We analyzed data from postmenopausal participants in 2 trials (NCT02524769 and NCT02835846) who chose vaginal estrogen as the primary overactive bladder treatment and used 0.5...” PMID 32791124 ↗ Aug 2020 |
| Known as | PVC | “This protocol is designed to study the effect and safety of 2 low-dose regimens of conjugated estrogen cream (PVC) given vaginally in postmenopausal women with atrophic vaginitis.” NCT00137371 ↗ |
| Action | Activate | “estrogen induces urothelial antimicrobial peptide (AMP) expression.” NCT02835846 ↗ |
| Route | Intravenous | “receive intravenous followed by oral conjugated estrogen” NCT00000601 ↗ |
| Route | Oral | “receive intravenous followed by oral conjugated estrogen” NCT00000601 ↗ |